About Salzman Group
Salzman Group is a company based in Beverly (United States) founded in 1996 by Andrew Salzman was acquired by Kalytera Therapeutics in May 2020. Salzman Group operates in a competitive market with competitors including Escient Pharmaceuticals, Nimbus Therapeutics, Septerna, Upstream Bio and ACELYRIN, among others.
- Headquarter Beverly, United States
- Founders Andrew Salzman
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website salzmangrp.com
- Acquired by Kalytera Therapeutics (May 2020)
- Latest Funding Round$492.8K (USD), Grant
Apr 2012
- InvestorsHHS
& 1 more
- Acquired byKalytera Therapeutics
(May 2020)
Funding Insights of Salzman Group
- Total Rounds 6
- Last Round Grant — $492,804
- First Round $263,034
(Jan 2011)
- Investors Count 1
All 6 funding rounds of Salzman Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Salzman Group
Salzman Group has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Kalytera Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Cannabinoid therapies for osteoporosis and bone healing are developed. | 2014 | kalytera.co | San Rafael, United States |
Investor details for Salzman Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Salzman Group
1 people are tracked at Salzman Group (1 in leadership).
| Name | Role | Group |
|---|---|---|
Andrew Salzman | Co-Founder & CEO | Leadership |
Complete people profiles for Salzman Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Salzman Group
4 dated milestones of Salzman Group across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Salzman Group is founded.
- Funding First funding round of $263K.
- Funding Latest funding round, Grant, of $493K.
- Exit Acquired by Kalytera Therapeutics.
Competitors of Salzman Group
Salzman Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Escient Pharmaceuticals, Nimbus Therapeutics, Septerna, Upstream Bio and ACELYRIN, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. |
Detailed competitors of Salzman Group
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Salzman Group
Complete news archive for Salzman Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Salzman Group
10 companies that operate in the same segment as Salzman Group (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Salzman Group
Salzman Group was founded in 1996 and raised its 1st funding round 15 years after it was founded.
Salzman Group is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.
Andrew Salzman is the current CEO of Salzman Group. They have also founded this company.
Salzman Group was founded in 1996 in Beverly, United States, within the biotechnology sector. Small molecule-based therapeutics for Crohns disease treatment are being advanced, with the lead candidate RvE1 derived from eicosapentaenoic acid and designed to bind the ChemR23 receptor on gut cells to reduce inflammation. This product is in Phase 1 clinical trials. Another candidate, R-107, is being developed for chlorine inhalation lung injury.
Salzman Group's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Salzman Group has 2 investors. Key investors include HHS, and Kalytera Therapeutics.
Yes. Salzman Group was acquired by Kalytera Therapeutics in May 2020.